Evidence map›Paper›PMID 29783985›Full record

ArticleVirology journal2018

The doses of plasmid backbone plays a major role in determining the HBV clearance in hydrodynamic injection mouse model.

Xian Wang, Jianmin Zhu, Yong Zhang, Yue Li, Tai Ma, Qun Li, Jiegou Xu, Long Xu

Open access · goldAbstract read
In one paragraph

Article in Virology journal, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.6field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Article
  3. Hepatitis B: Model Systems and Therapeutic Approaches.Journal of immunology research · 2024
    Review
  4. Article
  5. Review
  6. Frontiers in immunology · 2021
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Xian WangSchool of Basic Medical Sciences, Anhui Medical University, 81#Mei Shan Road, Hefei, 230032, Anhui, China.
Jianmin ZhuPediatric Translational Medicine Institute, Shanghai Children' s Medical Center, Shanghai Jiaotong University School of Medicine, Shanghai, China.
Yong ZhangDepartment of Spine Surgery, The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China.
Yue LiSchool of Basic Medical Sciences, Anhui Medical University, 81#Mei Shan Road, Hefei, 230032, Anhui, China.
Tai MaSchool of Basic Medical Sciences, Anhui Medical University, 81#Mei Shan Road, Hefei, 230032, Anhui, China.
Qun LiSchool of Basic Medical Sciences, Anhui Medical University, 81#Mei Shan Road, Hefei, 230032, Anhui, China.
Jiegou XuSchool of Basic Medical Sciences, Anhui Medical University, 81#Mei Shan Road, Hefei, 230032, Anhui, China.
Long XuSchool of Basic Medical Sciences, Anhui Medical University, 81#Mei Shan Road, Hefei, 230032, Anhui, China. xulong@ahmu.edu.cn.
Anhui Medical University · CNSecond Hospital of Anhui Medical University · CNShanghai Children's Medical Center · CN

Funding

Natural Science Foundation of China 81401281scientific research of BSKY from Anhui Medical University xj201401the 4th excellently scientific research of QNBJRC from Anhui Medical University 2013500023
6 · The paper itself

Abstract

backgroundHepatitis B virus (HBV) chronically infects approximately 350 million people worldwide, causing a major risk of liver disease and hepatocellular carcinoma (HCC). Many mouse models have been tried to establish HBV infection through injection with various HBV-containing plasmids. However, it is not well understood that different plasmids, all of which contain the similar HBV genome, even the same plasmids with different dose, results in opposite immune responses toward HBV.

methodsIn this study, we investigated the role of HBV-containing plasmid backbones and the HBcAg in determining the HBV persistence. C57BL/6 mice were injected hydrodynamically with 6 μg or 20 μg of WT pAAV/HBV1.2 plasmid, e/core-null pAAV/HBV1.2 plasmid, or none-HBV genome pAAV/control plasmid. Serum levels of HBV-related markers were measured by quantitative immunoradiometric assay (IRMA). Liver HBcAg expression was detected by immunohistochemical staining. The mRNA levels of cytokines and Th1-related immune factors were quantified by qRT-PCR.

resultsAll mice injected with 6 μg of the pAAV/HBV1.2 plasmid shows HBsAg positive at week 6 after hydrodynamic injection (AHI) as previously investigated. However, the mice injected with 20 μg pAAV/HBV1.2 or 6μgpAAV/HBV1.2 plus 14μgpAAV/control plasmid results in HBV clearance within 4 weeks AHI, indicating the anti-HBV activity is induced by 20 μg plasmid DNA, but not by the inserted viral genome. This anti-HBV activity is independent of HBcAg and Toll like receptor (TLR) signaling pathway, since the lack of HBcAg in pAAV/HBV1.2 plasmid or stimulation with TLRs agonists does not influence the kinetics of serum HBsAg in mice. The mRNA levels of t-bet and cxcr3 were dramatically up-regulated in the liver of the mice injected with 20 μg plasmid DNA.

conclusionOur studies demonstrate that plasmid backbones are responsible for modulating immune responses to determine HBV persistence or clearance in our HBV mouse model by hydrodynamic injection of HBV-containing plasmid, and Th1 cells play key roles on HBV clearance.

Indexed as

AnimalsBiolisticsDependovirusDisease Models, AnimalGene DosageGene Expression RegulationGenetic VectorsHepatitis BHepatitis B Core AntigensHepatitis B Surface AntigensHepatitis B virusHost-Pathogen InteractionsHydrodynamicsInterferon Type ILiverMaleCxcr3 protein, mouseHepatitis B Core AntigensHepatitis B Surface AntigensInterferon Type IReceptors, CXCR3T-bet Transcription FactorT-Box Domain ProteinsToll-Like ReceptorsHBcAgHepatitis B virusHydrodynamic injectionMouse modelPlasmid backbone

Identifiers

PMID29783985
PMCPMC5963156
OpenAlexW2806179530

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.